Clinical Trials Browser

Carcinoma, Non-Small-Cell Lung × ensartinib × Clear all

NCT07354061 2026-04-01

TD-ENSEMBLE

Phase 1/2 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT04837716 2026-02-19

Ensartinib, Carboplatin, Pemetrexed and Bevacizumab for the Treatment of Stage IIIC or IV or Recurrent ALK-Positive Non-small Cell Lung Cancer

Phase 1 Active not recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT02767804 2025-10-14

eXalt3: Study Comparing X-396 (Ensartinib) to Crizotinib in ALK Positive Non-Small Cell Lung Cancer (NSCLC) Patients

Phase 3 Active not recruiting

290 enrolled 3 FDA

Carcinoma, Non-Small-Cell Lung

NCT06955325 2025-05-06

UPLIFT

Phase 3 Not yet recruiting

Carcinoma, Non-Small-Cell Lung

NCT06779539 2025-01-17

Neoadjuvant Ensartinib in ALK Positive Resectable Stage II to III Non-Small Cell Lung Cancer

Phase 2 Not yet recruiting

Carcinoma, Non-Small-Cell Lung

NCT06780839 2025-01-17

Adjuvant Treatment of ALK-positive Non-small Cell Lung Cancer with Ensartinib Guided by MRD

Phase 2 Not yet recruiting

Carcinoma, Non-Small-Cell Lung

NCT06563999 2024-12-10

NUMER

Phase 2 Recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT05491811 2024-09-19

EAGLE

Phase 2 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT05341583 2024-08-23

Ensartinib as Adjuvant Treatment in Anaplastic Lymphoma Kinase (ALK) Positive Non-small Cell Lung Cancer

Phase 3 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT05241028 2023-10-10

Adjuvant Therapy of Ensartinib in Stage IB-IIIA ALK-positive Non-small Cell Lung Cancer

Phase 2 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT03215693 2023-08-16

X-396 Capsule in Patients With ALK-positive Non-small Cell Lung Cancer Previously Treated With Crizotinib

Phase 2 Unknown

Carcinoma, Non-Small-Cell Lung

NCT03574402 2022-12-06

TRUMP

Phase 2 Unknown

Carcinoma, Non-Small-Cell Lung

NCT04146571 2022-10-20

Expanded Access to Ensartinib for Participants With ALK+ NSCLC

Carcinoma, Carcinoma, Non-Small-Cell Lung

NCT02898116 2022-10-10

Phase 1/2 Study of Ensartinib and Durvalumab, in ALK-rearranged Non-small Cell Lung Cancer

Phase 1/2 Completed

2 enrolled 8 charts

Carcinoma, Carcinoma, Non-Small-Cell Lung

NCT05380024 2022-08-18

A Study of Ensartinib as Neoadjuvant Therapy for Patients With ALK Positive Resectable Non-Small Cell Lung Cancer

Phase 2 Unknown

Carcinoma, Non-Small-Cell Lung

NCT05498064 2022-08-11

A Real World Study of Ensartinib in Advanced ALK-positive NSCLC

Carcinoma, Non-Small-Cell Lung

NCT05186506 2022-01-11

A Study Comparing Ensatinib Versus Platinum-Based Chemotherapy as Adjuvant Treatment for Stage II-IIIA ALK -Positive Non-Small Cell Lung Cancer

Phase 2 Not yet recruiting

Carcinoma, Non-Small-Cell Lung

NCT01625234 2021-10-06

Phase 1/2 Study of X-396, an Oral ALK Inhibitor, in Patients With ALK-positive Non-Small Cell Lung Cancer

Phase 1/2 Completed

Carcinoma, Non-Small-Cell Lung, Neoplasms

NCT04415320 2020-06-04

X-396 (Ensartinib) Capsules in ALK-Positive NSCLC Patients With Brain Metastases

Phase 2 Unknown

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung

NCT03510611 2019-07-24

A Study to Investigate the Food Effect on the Pharmacokinetics of Ensartinib Capsules in Chinese Healthy Volunteers.

Phase 1 Completed

Carcinoma, Non-Small-Cell Lung